On October 14, 2021 Apmonia Therapeutics’ lead candidate TAX2 (AP-01) in ovarian cancer therapy, and shows how selective antagonization of TSP-1:CD47 axis is a new powerful way of activating anti-tumor immunity (Press release, Apmonia Therapeutics, OCT 14, 2021, View Source [SID1234591413]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

We believe our innovative technology to be a safer and effective approach with the potential to treat multiple indications of solid tumors.